[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100492855":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":19,"responsibleParty":35,"collaborators":7,"id":37,"slug":7,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":46,"enrollmentInfo":47,"targetDuration":50,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":22,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"National Society for Neurosonology and Cerebral Circulation","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Igor A Voznjuk, Prof","First St. Petersburg State Medical University named after I.P. Pavlov","STUDY_DIRECTOR",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Tatiana Kharitonova","CONTACT","+79217450431","tvh2001@mail.ru",[20],{"facility":21,"status":22,"city":23,"state":7,"zip":7,"country":24,"countryCode":25,"cosmosGeoPoint":26,"geoPoint":31,"contacts":32},"St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze","RECRUITING","Saint Petersburg","Russia","RU",{"type":27,"coordinates":28},"Point",[29,30],30.31413,59.93863,{"lat":30,"lon":29},[33],{"name":34,"role":16,"phone":7,"phoneExt":7,"email":7},"Ekaterina Gogoleva",{"type":36,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100492855",false,"NCT05697575","Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","Non-interventional Observational Study to Evaluate the Efficacy and Safety of Non-immune Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice","REPIN","Inclusion Criteria:\n\n* Age 18-85 ;\n* Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;\n* Thrombolytic therapy with the drug \"non-immunogenic staphylokinase\" is planned or has already been performed.\n\nExclusion Criteria:\n\n* Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;\n* The presence of a contraindication to thrombolytic therapy of ischemic stroke;\n* Pregnancy or lactation.","ALL","18 Years","85 Years",{"count":48,"type":49},336,"ESTIMATED","1 Year","OBSERVATIONAL","The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.",[54],"Acute Stroke",[56,57,58],"stroke thrombolysis","acute ischemic stroke","reperfusion","2026-04-09",{"date":61,"type":62},"2026-04-13","ACTUAL",{"date":64,"type":62},"2023-02-01",{"date":66,"type":49},"2030-05-10",{"name":5,"class":6},1]